Keywords: PI(3)K inhibitrs, Drug design, Intellikine, Cancer, Asthma, Rheumatoid arthritis
3D structure of key drug target sheds light on how to design better drugs
Article | 13 January 2010
California, USA-based small-molecule drug developer Intellikine has announced the publication of an article, titled "The p110delta structure: mechanisms ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
